BioCentury
ARTICLE | Finance

Ebb & Flow

September 10, 2001 7:00 AM UTC

A big week for FDA panel reviews will provide a major test for the biotech space in the wake of last week's post-Labor Day let-down.

The big newsmakers will be Tuesday's Oncologic Drugs Advisory Committee review of the BLA for Idec's Zevalin ibritumomab radiolabeled antibody to treat non-Hodgkin's lymphoma (NHL) and follicular NHL refractory to IDPH's Rituxan, followed on Wednesday by the Anti-Infective Drugs Advisory Committee discussion of Eli Lilly's Xigris sepsis biologic...